We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $3.85B
1-Year Est. Return 32.11%
This Fund
S&P 500
This Quarter Est. Return
+10.55%
1 Year Est. Return
+32.11%
3 Year Est. Return
+93.86%
5 Year Est. Return
+112.79%
10 Year Est. Return
+380.9%
AUM
$3.14B
AUM Growth
+$728M
Cap. Flow
+$534M
Cap. Flow %
17.01%
Top 10 Hldgs %
37.86%
Holding
6,828
New
511
Increased
3,030
Reduced
2,253
Closed
625

Sector Composition

Rank Sector Weight
1 Technology 21.21%
2 Consumer Discretionary 7.37%
3 Financials 6.36%
4 Healthcare 5.92%
5 Industrials 5.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GWIIW
6651
DELISTED
Good Works II Acquisition Corp. Warrant
GWIIW
-1,022
Closed
AMOV
6652
DELISTED
America Movil SAB de CV
AMOV
-402
Closed -$7K
RAAS
6653
DELISTED
Cloopen Group Holding Limited American Depositary Shares (each representing six (6) Class A Ordinary Shares)
RAAS
$0 ﹤0.01%
+242
New +$537
TBSA
6654
DELISTED
TB SA Acquisition Corp Class A Ordinary Share
TBSA
-1,446
Closed -$15K
BACA.U
6655
DELISTED
Berenson Acquisition Corp. I Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant
BACA.U
-100
Closed -$1K
MYOV
6656
DELISTED
Myovant Sciences Ltd.
MYOV
-269,319
Closed -$7.26M
VVNT
6657
DELISTED
Vivint Smart Home, Inc. Class A Common Stock
VVNT
-5,008
Closed -$60K
FSTX
6658
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
-3,724
Closed -$24K
HERA
6659
DELISTED
FTAC Hera Acquisition Corp. Class A Ordinary Shares
HERA
-2,013
Closed -$20K
HERAU
6660
DELISTED
FTAC Hera Acquisition Corp. Units
HERAU
-163
Closed -$2K
FRSGU
6661
DELISTED
First Reserve Sustainable Growth Corp. Unit
FRSGU
-8
Closed
LION
6662
DELISTED
Lionheart III Corp Class A Common Stock
LION
-276
Closed -$3K
FPAC.U
6663
DELISTED
Far Peak Acquisition Corporation Units, each consisting of one Class A ordinary share, and one-third of one redeemable warrant
FPAC.U
-235
Closed -$2K
LOKM
6664
DELISTED
Live Oak Mobility Acquisition Corp.
LOKM
-290
Closed -$3K
CNCE
6665
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
-7,398
Closed -$43K
RUBY
6666
DELISTED
Rubius Therapeutics, Inc
RUBY
$0 ﹤0.01%
25
MLAI
6667
DELISTED
McLaren Technology Acquisition Corp. Class A Common Stock
MLAI
-590
Closed -$6K
FTEV
6668
DELISTED
FinTech Evolution Acquisition Group
FTEV
-270
Closed -$3K
FTEV.U
6669
DELISTED
FinTech Evolution Acquisition Group Units, each consisting of one Class A Ordinary Share, and one-third of one redeemable warrant
FTEV.U
-482
Closed -$4.89K
HPX.U
6670
DELISTED
HPX Corp. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant
HPX.U
-153
Closed -$1.84K
LHDX
6671
DELISTED
Lucira Health, Inc. Common Stock
LHDX
-12,972
Closed -$1K
OIIM
6672
DELISTED
02Micro International
OIIM
-23,216
Closed -$104K
MLAIU
6673
DELISTED
McLaren Technology Acquisition Corp. Unit
MLAIU
-1,380
Closed -$14K
ALBO
6674
DELISTED
Albireo Pharma Inc
ALBO
-1,004
Closed -$22K
OPNT
6675
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
-744
Closed -$15K

Similar funds

Tower Research Capital (TRC)'s Q1 2023 Portfolio in Review

As of Q1 2023, Tower Research Capital (TRC) held 6,828 positions worth $3.14B, up 30% from $2.41B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tower Research Capital (TRC) deployed $534M of net new capital in Q1 2023, opening 511 new positions and adding to 3,030 existing holdings. Its largest new stake was iShares Russell 2000 Growth ETF: 100,561 shares worth $22.8M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was iShares Russell 2000 ETF, an estimated $52.8M trimmed.

  • Tower Research Capital (TRC)'s largest Q1 2023 buy was iShares Russell 2000 Growth ETF: 100,561 shares worth $22.8M.
  • Tower Research Capital (TRC) added most to State Street SPDR S&P 500 ETF Trust in Q1 2023, an estimated $204M increase.
  • Tower Research Capital (TRC)'s biggest Q1 2023 reduction was iShares Russell 2000 ETF, cutting an estimated $52.8M.
  • Tower Research Capital (TRC) fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $7.26M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 38% of its $3.14B portfolio in Q1 2023.
  • Tower Research Capital (TRC) opened 511 new positions and closed 625 in Q1 2023.
  • Tower Research Capital (TRC)'s portfolio value rose 30% quarter-over-quarter to $3.14B.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.